| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Nektar Therapeutics | Rezpegaldesleukin (LY3471851 or REZPEG) | Systemic lupus erythematosus (SLE) | Phase 2 | Trial Discontinued | Subcutaneous | Immunology |
| NeOnc Technologies Holdings Inc. | NEO100-01 | Glioblastoma (GBM) | Phase 2 | Ongoing | Inhalation | Oncology |
| NeOnc Technologies Holdings Inc. | NEO212 | Newly diagnosed gliomas | Phase 2a | Trial Planned | Oral | Oncology |
| Neumora Therapeutics Inc. | Navacaprant (NMRA-140) - (KOASTAL-1) | Major depressive disorder | Phase 3 | Data Released | Oral | Psychiatric |
| Neumora Therapeutics Inc. | Navacaprant (NMRA-140) - (KOASTAL-1) | Major depressive disorder | Phase 3 | Data Released | Oral | Psychiatric |
| Neumora Therapeutics Inc. | Navacaprant (NMRA-140) | Bipolar Depression | Phase 2 | Ongoing | oral | Psychiatric |
| Neuphoria Therapeutics Inc. | BNC210 - (AFFIRM-1) | Social Anxiety Disorder (SAD) | Phase 3 | Data Released | oral | Psychiatric |
| Neurocrine Biosciences Inc. | Osavampator (NBI-1065845) - (SAVITRI) | Major depressive disorder | Phase 3 | Ongoing | Oral | Psychiatric |